GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Mega Genomics 6667.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

6.90

—

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥288.3m

FY2019FY2025

Net income

CN¥30.7m

FY2019FY2025

Free cash flow

−CN¥19.5m

FY2019FY2025

Shareholders' equity

CN¥712.7m

FY2019FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
RevenueCN¥288.3mCN¥191.6mCN¥151.3mCN¥145.7mCN¥237.2mCN¥203.2mCN¥123.7m
Gross profitCN¥136.9mCN¥139.2mCN¥88.3mCN¥81.7mCN¥166.7mCN¥146.2mCN¥78.5m
Research and developmentCN¥20.2mCN¥22.4mCN¥24.7mCN¥19.4mCN¥11.4mCN¥4.4mCN¥4.4m
Operating incomeCN¥45.6mCN¥64.6mCN¥18.9mCN¥2.5mCN¥109.8mCN¥111.5mCN¥64.3m
Net incomeCN¥30.7mCN¥52.5mCN¥30.0m−CN¥17.6mCN¥79.0mCN¥79.1mCN¥29.7m
Diluted earnings per share0.140.260.15-0.080.390.330.12

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assetsCN¥971.0mCN¥861.4mCN¥796.5mCN¥823.2mCN¥900.8mCN¥453.6mCN¥263.7m
Cash and short-term investmentsCN¥508.2mCN¥571.9mCN¥518.3mCN¥466.4mCN¥278.9mCN¥208.4mCN¥52.6m
Total liabilitiesCN¥258.3mCN¥144.4mCN¥151.7mCN¥102.3mCN¥90.6mCN¥277.2mCN¥266.4m
DebtCN¥34.3mCN¥37.8mCN¥48.6mCN¥11.0mCN¥11.6mCN¥22.8mCN¥36.9m
Shareholders' equityCN¥712.7mCN¥717.0mCN¥644.8mCN¥720.9mCN¥810.1mCN¥176.4m−CN¥2.7m
Shares outstanding224m201m202m212m201m239m239m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−CN¥19.3mCN¥66.7mCN¥163.7m−CN¥8.1mCN¥35.7mCN¥102.8mCN¥37.3m
Capital spending−CN¥184,308−CN¥904,042−CN¥36.1m−CN¥6.1m−CN¥5.2m−CN¥1.0m−CN¥761,000
Free cash flow−CN¥19.5mCN¥65.8mCN¥127.6m−CN¥14.1mCN¥30.6mCN¥101.8mCN¥36.5m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Mar 2024Dec 2023Sept 2023
RevenueCN¥224.8mCN¥190.3mCN¥94.8mCN¥66.4mCN¥107.3mCN¥62.6mCN¥52.4mCN¥30.6m
Gross profitCN¥74.4mCN¥65.6mCN¥70.2mCN¥58.0mCN¥69.6mCN¥40.6mCN¥23.0mCN¥13.4m
Operating incomeCN¥33.8m−CN¥1.8mCN¥39.3mCN¥13.3mCN¥31.3mCN¥18.2m−CN¥17.9m−CN¥5.0m
Net incomeCN¥28.9m−CN¥275,290CN¥31.8mCN¥9.4mCN¥37.0mCN¥21.6m−CN¥5.1m−CN¥3.0m
Diluted earnings per share0.14-0.000.140.050.180.11-0.03-0.01
Cash from operations—−CN¥17.0m−CN¥1.0mCN¥66.0mCN¥14.0mCN¥8.0mCN¥112.0mCN¥56.0m
Capital spending——————−CN¥27.0m−CN¥13.0m
Free cash flow——————CN¥85.0mCN¥43.0m
Total assetsCN¥968.0mCN¥971.0mCN¥802.6mCN¥861.4mCN¥832.1mCN¥970.6mCN¥796.5mCN¥929.2m
Cash and short-term investmentsCN¥495.2mCN¥508.2mCN¥536.0mCN¥571.9mCN¥508.9mCN¥593.7mCN¥518.3mCN¥613.9m
DebtCN¥10.4mCN¥34.3mCN¥44.1mCN¥37.8mCN¥41.4mCN¥4.7mCN¥48.6mCN¥14.6m
Shareholders' equityCN¥706.2mCN¥712.7mCN¥713.4mCN¥717.0mCN¥662.6mCN¥773.0mCN¥644.8mCN¥752.2m

Financial ratios

Data as of 3 Nov 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin47.5%72.7%58.4%56.1%70.3%72.0%
Operating margin13.8%33.7%24.7%-14.2%43.3%54.8%
Net margin10.9%27.4%19.9%-12.1%33.3%38.9%
Return on equity4.4%7.3%4.7%-2.9%11.4%44.8%
Return on assets3.2%6.1%3.8%-2.5%10.2%17.4%
Free cash flow yield-1.1%3.6%11.5%-0.5%2.2%—
Revenue growth50.5%8.5%3.8%-38.6%16.7%64.3%
Earnings growth-40.0%50.0%-270.5%-122.3%-0.1%166.4%
Current ratio3.64x6.90x5.84x7.62x9.82x1.36x
Debt to equity0.04x0.03x0.05x0.02x0.02x0.90x
Equity ratio73.4%83.2%81.0%87.6%89.9%38.9%
Interest coverage25.70x32.20x33.25x-28.79x14.88x6.73x
R&D as a share of sales7.0%11.7%14.8%13.3%4.8%2.2%
Buybacks as a share of market value1.8%-12.8%4.5%-5.4%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue25.5%7.2%—
Operating income162.4%-16.4%—
Net income—-17.2%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin57.5%57.4%62.4%—
Operating margin23.0%16.9%29.0%—
Net margin17.3%12.3%20.8%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings47.339.463.1-142.9
Price to sales5.010.812.517.3

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.